Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bladder preservation with Disitamab Vedotin + toripalimab and PLND in HER2-positive muscle-invasive bladder urothelial carcinoma
ChiCTR2400081555Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in transitional cell carcinoma of the bladder (TCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: 2-year disease-free survival rate of intact bladder (2-year BI-DFS). Planned start Mar 2024; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2400081555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081555.